Accordingly, the final sample consisted of a total of 1,588 coronary patients (Figure 1 ). All data were prospectively collected and recorded onto computerized database registries that remained consistent over the study period. Information on demographics, comorbidities, medical and surgical history, operative details and postoperative events during the hospital stay were all registered. The study protocol was approved by the local Institutional Review Board and received full approval (nr. 0014506); patient consent was waived.
Clinical and Surgical Management
Preoperative management, anesthetic, and surgical techniques were standardized for all patients and have been previously reported. 15 During the surgical hospitalization, all patients underwent preoperative coronary angiography, transthoracic echocardiography (TTE), and color-Doppler ultrasound of epiaortic vessels. All patients who either received a 300-mg oral loading dose of clopidogrel or daily oral regimen of 75 mg constituted the clopidogrel group as previously described. 7 Generally, all patients in both groups received aspirin within 24 h of their admission. Preoperative clopidogrel and aspirin, however, were discontinued on the day of hospitalization, whereas other medications were routinely omitted on the day of operation and restarted after the operation (first postoperative day), unless clinically contraindicated. All procedures were performed through a median sternotomy approach, and cardiopulmonary bypass (CPB) was of standardized fashion, with ascending aortic cannulation and right atrial cannulation. Intravenous heparin was given 3 mg/kg of weight and the activated clotting time (ACT) was maintained at >450 s. In addition, in all cases tranexamic acid was given i.v. after the induction of anesthesia until operation end (20 mg/kg for the first hour and 2 mg/kg thereafter).
After CPB the circulating heparin (300 UI/kg) was antagonized with protamine sulfate at a ratio of 1 mg per 1 mg heparin. Prolonged ACT after surgery was treated with an additional dose of protamine sulfate. When visual inspection indicated microvascular bleeding or cardiotomy reservoir bleeding in excess (generally 200 ml at the end of the operation), the patient received an assessment of the hemostasis/coagulation profile through thromboelastography (TEG; Haemoscope, Morton Grove, IL, USA) with and without heparinase. Therefore, perioperative need for blood products, including fresh frozen plasma (FFP) and platelets, was determined on an individual, patient-by-patient basis. In general, homologous red cells were given intraoperatively to maintain a hemoglobin concentration >7 g/dl, or a hematocrit >20% during CPB, or given postoperatively when hemoglobin was <8 g/dl. Additional blood product transfusions were, however, at the discretion of the individual surgeon or anesthesiologist. Aprotinin or other hemostatic agents were not used. At the end of surgery, patients were transferred to the intensive care unit (ICU) and managed according to the unit protocols. 15 
Endpoints and Definitions
The primary endpoint was the impact of preoperative clopidogrel on transfusion of any blood product (packed red blood cells [pRBC] , FFP, and platelets) with reference to the timing of its discontinuation. Other secondary outcomes including hemorrhagic complications and hospital mortality were also analyzed.
Blood product transfusions were quantified in units. Hemorrhagic complications were defined as the need for re-exploration for bleeding or cardiac tamponade. Generally, postoperative bleeding was defined as >300 ml during the first hour; >250 ml during the second hour; >200 ml during the third hour; or a total of ≥1,000 ml during the first 6 h. The decision for hemorrhagic re-exploration, however, rested with the surgeons. Chest tube outputs were used as a measure of bleeding loss, and the present analysis was based on the total volume of loss during the first 24 h of the patient's stay in the ICU. Acute kidney injury (AKI) was defined according to the consensus RIFLE (Risk, Injury, Failure, Loss of function, End-stage renal disease) criteria using the maximal change in serum creatinine and estimated glomerular filtration rate (eGFR) during the first 7 postoperative days compared with baseline values before surgery. 16 A diagnosis of cerebrovascular accident (CVA) was made if there was evidence of new neurological deficit with morphological substrate confirmed on computed tomography or magnetic resonance imaging. Respiratory failure was defined as mechanical ventilation >48 h. Other analyzed variables were defined as previously described. 15 
Statistical Analysis
Clinical data were prospectively recorded and tabulated with Microsoft Excel (Microsoft, Redmond, WA, USA). Continuous variables were tested for normal distribution using the Kolmogorov -Smirnov test and compared between groups with unpaired Student's t-test for normally distributed data; otherwise, the Mann -Whitney U-test was used. In the case of dichotomous variables, group differences were examined using Pearson chi-square or Fisher exact tests as appropriate.
In an attempt to control for selection bias related to the choice of preoperative clopidogrel therapy, a propensity score for the likelihood of receiving clopidogrel was developed and multivariate logistic regression analysis to calculate propensity score was applied. The propensity score was based on the following variables: age (years), gender, prior acute myocardial infarction, prior percutaneous coronary intervention, emergency status, reoperation, body mass index, hypertension, diabetes, dyslipidemia, peripheral vascular disease, prior CVA, chronic obstructive pulmonary disease, EUROscore (additive), eGFR, preoperative hemoglobin, preoperative aspirin, calcium channel blocker, β-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, left main stem stenosis, preoperative cardiac rhythm (sinus rhythm, paroxysmal atrial fibrillation [AF], or pacemaker-guided rhythms), type of operation (CABG isolated or combined with a valvular procedure), and number of grafts.
This process generated a propensity score between 0 and 1, and patients receiving preoperative statin therapy were matched 1:1 to patients not receiving it, using the Rosenbaum optimal matching algorithm. 17 This approach minimizes the overall distance between observations and was conducted using Mahalanobis distance within propensity score calipers (no matches outside the calipers). 17 After the propensity score match was performed, we assessed differences between the 2 groups as given here. Absolute standardized differences were estimated to evaluate the prematch imbalance and post-match balance. 17 An absolute standardized difference of 0% indicates no residual bias, and differences <10% are considered inconsequential. 18 Then univariable analyses for the need of blood transfusion with reference to the timing of its discontinuation were carried out; the obtained predictors were then tested in a multivariable mode. A stepwise approach was used and confirmed by backward and forward methods. The models were built using variables that had P<0.20 in univariate mode. The significance within the models was evaluated using the Wald test, whereas the strength of the association of variables with blood transfusion requirement was estimated by calculating the odds ratio (OR) and 95% confidence intervals (CIs). The model was calibrated using the Hosmer -Lemeshow goodness-of-fit test, as well as residual diagnostics (deviance and dfBetas); model discrimination was evaluated using the area under the receiver operating characteristic (ROC) curve. All tests were 2-sided with the alpha level set at 0.05 for statistical significance. Extracted database variables were tabulated using Microsoft Excel (Microsoft) and statistical analysis was done using SPSS release 16.0 for Windows (SPSS, Chicago, IL, USA) and NCCS 2007, release 7.1 for Windows (Kaysville, UT, USA). Considering sample size calculations (study power of 80% and α of 0.05) to detect a 1-unit difference in pRBC transfusion rates (n=70 patients for each group) and re-exploration for bleeding (n=137 patients for each group), the present study was powered to adequately explore the main endpoints. 7 
Results

Subject Characteristics
Among 1,588 patients in the study cohort, 279 (18%) were on clopidogrel treatment, and 1,309 (82%) were not. The mean patient age was 68.3±9.5 years and 372 (23%) were female. Operations were performed on an emergency basis in 236 cases (16%). Isolated CABG was performed in 1,163 subjects (73%), while concomitant valve surgery was done in 425 (27%). Postoperatively, re-exploration for bleeding was necessary in 54 patients (3%), and 954 (60%) required blood component transfusions. Hospital mortality was 2.3% (30/1,588).
Baseline characteristics of the study group are listed in Table 1 . Considering the unmatched subject group, the percentage of patients who had acute myocardial infarction (63% vs. 51%, P<0.001) or who underwent percutaneous coronary intervention (23% vs. 11%, P<0.001) was higher in the clopidogrel group compared with the control group. Similarly, a higher rate of emergency procedures (70% vs. 13%, P<0.001) and a lower rate of combined operations (18% vs. 29%, P< 0.001) characterized the clopidogrel group. After propensity score matching, the clopidogrel and control group appeared perfectly comparable with regard to preoperative and perioperative characteristics and risk, and the average EuroSCORE risk scores were not statistically significantly different (6.2±3.3 vs. 6.2±3.7, P=0.849). In addition, post-match standardized differences for all measured covariates were <10% (most were <5%), suggesting substantial covariate balance across groups. No differences were detected between the 2 groups with regard to preoperative aspirin regimen (49% vs. 51%, P=0.229). With regard to clopidogrel stop, 91% of patients (211/255) discontinued clopidogrel within 5 days of surgery, while 9% discontinued the antiplatelet drug >5 days before surgery. A total of 23% of subjects underwent surgery within 24 h of receiving clopidogrel.
Blood Product Transfusion Requirements
In the propensity score-matched subjects, blood transfusions were given in 313 patients (61%), and the annual rates did not change over the study period (P=0.332). Patients in the clopidogrel group were more likely to have received transfusions (56% vs. 45%, P<0.013), particularly for those who took clopidogrel within 24 h of operation (72% vs. 45%, P<0.001). No differences were detected for the rate of pRBC and FFP transfusions between patients receiving clopidogrel and those who did not (53% vs. 48%, P=0.149, and 51% vs. 49%, P=0.913, respectively). Similar data were seen for the amount of units of pRBC and FFP (P=0.792 and P=0.876, respectively; Table 2 ). Conversely, clopidogrel was found to be associated with a higher rate of platelet transfusion (63% vs. 37%, P<0.001) and a higher number of platelet units (P=0.009; Table 2; Figure 2 ). No differences were detected for blood loss during the first 24 h between patients with preoperative clopidogrel compared with those without it (P=0.591). Independent predictors for blood product transfusion are listed in Table 3 . Clopidogrel stop within 5 days before surgery was independently associated with transfusion requirement. Other independent predictors were emergency status, female gender, basal hemoglobin, preoperative eGFR, and CPB time. Aspirin alone or its association with clopidogrel did not emerge as significant risk factors for transfusions (OR, 1.50; 95%CI: 0.68-3.31; and OR, 1.25; 95%CI: 0.77-2.03, respectively).
In-Hospital Outcomes
Postoperative outcomes of the propensity score-matched subjects are summarized in Table 2 . Hemorrhagic complications occurred in 16 patients (3%) without differences between the 2 groups (3% vs. 4%, P=0.611). Clopidogrel was not an independent predictor for hemorrhagic complications (OR, 0.77; 95%CI: 0.28-2.10). As noted in the previous section, aspirin alone or its association with clopidogrel did not emerge as significant risk factors for hemorrhagic complication (OR, Optimal Timing of Clopidogrel Discontinuation After CABG Circulation Journal Vol.75, December 2011 There were also no significant differences in the rates of respiratory failure (P=0.901), perioperative myocardial infarction (P=0.983), intra-aortic balloon pump use (P=0.757), inotropic support need (P=0.927), CVA occurrence (P=0.609), or postoperative AF (P=0.236) between patients receiving clopidogrel and those without it. Only patients receiving clopidogrel within 24 h of operation had a higher prevalence of postoperative AKI (P=0.037).
Ventilation time, ICU stay and length of hospitalization were also similar between clopidogrel recipients compared with the control group (P=0.995, P=0.628, and P=0.667, respectively). Again, the unadjusted operative mortality rate was not significantly different between the 2 groups (2.4% vs. 2.4%, P= 0.999).
Discussion
Clopidogrel has been demonstrated to be effective in the setting of acute coronary syndrome, stent thrombosis prevention, and non-ST elevation acute myocardial infarction. 1 Its irreversible platelet inhibition, however, represents a concern for upcoming coronary surgery, because of the related increased risk of perioperative bleeding and blood transfusion requirement. 4-12 The latter represent significant causes of morbidity and mortality after cardiac surgery, involving 2-3% of the operated patients, and also of increased hospital stay and costs. 21, 22 As a consequence, several studies have analyzed the impact of preoperative clopidogrel on hemorrhagic complications. [4] [5] [6] [7] [8] [9] [10] [11] [12] The present data confirm that preoperative clopidogrel was an independent predictor for transfusion of blood products, supporting the discontinuation of clopidogrel >5 days before surgery in order to avoid the risk of transfusion. The present data confirm the American College of Cardiology/American Heart Association (ACC/AHA) guideline recommendations, which certainly endorse the acute use of clopidogrel, recommending its withholding for at least 5 days before CABG surgery. 22 The optimal time delay, however, between the last dose of clopidogrel and the timing of coronary surgery is not clear, despite the fact that platelet function recovers completely 7 days after clopidogrel cessation. 9,11,12 On the one hand, the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial suggests that the incidence of major bleeding is higher in patients receiving clopidogrel within 5 days of surgery compared with those taking clopidogrel >5 days before surgery. 19 The Mehta et al study, which evaluated 2,858 patients who underwent CABG at 264 hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/ AHA Guidelines (CRUSADE) Initiative, confirmed the benefits of delaying CABG surgery for >5 days after the discontinuation of clopidogrel. 5 On the other hand, Herman et al recently demonstrated that only patients receiving clopidogrel within 24 h of coronary surgery are at increased risk for transfusion and hemorrhagic complications, 9 and Ascione et al found that 48 h was the optimal time delay between the last CL stop intervals were defined as follows: < -24 h, CL discontinued from 0 to 24 h before the operation; 2 days, CL discontinued from 24 to 48 h before operation; 3 days, CL discontinued from 48 to 72 h; 4 days, CL discontinued from 72 to 96 h; 5 days, CL discontinued from 96 to 110 h; >5 days, CL discontinued >5 days before operation. OR, odds ratio; CI, confidence interval. Other abbreviations see in Table 1 .
clopidogrel dose and the timing of surgery. 14 Certainly, the timing of surgery for patients receiving clopidogrel is a key issue in order to minimize the increased risk for transfusion and hemorrhagic complications. The benefits of delaying surgery after the administration of clopidogrel must be weighed against the potential risks of ischemic or thrombotic events as well as the economic consequences of extended hospital stay. Additionally, the great majority of patients suitable for coronary surgery are not delayable, because of their hemodynamic compromise or coronary anatomy. Mehta et al reported that 87% of patients receiving preoperative clopidogrel required surgery within 5 days of their last clopidogrel dose. 5 In the present study, 83% of patients receiving preoperative clopidogrel underwent surgery within 5 days of its discontinuation, while 61% underwent surgery within 48 h. Therefore, in light of the importance of blood product transfusion to patient outcome, therapeutic strategies to minimize bleeding events and the likelihood of transfusion in CABG patients receiving clopidogrel, are crucial. Many studies in recent years have advocated the restricted use of intraoperative and postoperative blood transfusion, because of the increase in postoperative infection, acute lung injury, and all-cause mortality. 23, 24 In particular, platelet transfusion has been demonstrated to confer an increased risk for adverse early and late morbid events. 23, 24 The present study showed that, although the overall transfusion risk was higher in clopidogrel recipients either on univariate and multivariate analysis, only units of transfused platelet differed between patients receiving clopidogrel and those without it (Figure 2) . Controversial data exist, however, concerning transfusion product requirement after clopidogrel exposure. Englberger et al reported increased platelet and FFP transfusions in patients receiving clopidogrel within 3 days of surgery, 25 while Karabulut et al did not observe a transfusion increase in clopidogrel recipients. 26 Vaccarino et al found that only FFP transfusion rate was significantly higher in the clopidogrel group, 27 whereas other studies demonstrated an increased number of blood units compared with FFP and platelet unit consumption. 5,7,11 A possible explanation is related to the retrospective nature of the aforementioned studies, inevitably subjected to bias by unmeasured confounders, particularly with regard to preoperative patient factors. Several of these studies had significant discrepancies in preoperative baseline characteristics such as age, body mass index, and comorbidities, or did not consider preoperative hemoglobin levels, with possible confounding effects on either hemorrhagic and transfusion outcomes. 5-7,11,12 The present study was adjusted for these baseline differences by assessment of the preoperative role of clopidogrel while stratifying on the propensity score. Patient groups were balanced for demographics, comorbidities as well as for preoperative eGFR and hemoglobin levels. Therefore, the use of procoagulant and platelet-protective drugs, and closer attention to maintaining a dry surgical field prior to sternal closure should be considered in upcoming coronary surgery patients receiving clopidogrel.
In the present study, no effect of preoperative clopidogrel was observed with reference to hemorrhagic complications (re-exploration for bleeding or cardiac tamponade). Hemorrhagic complications occurred without significant differences between patients taking preoperative clopidogrel compared with those without it. The present findings are in agreement with those of Kim et al, who observed that preoperative clopidogrel was not associated with an increased risk of hemorrhagic complications (OR, 1.24; 95%CI: 0.63-2.41). 28 Similarly, we observed no mortality differences between patients taking clopidogrel and those without it, and no significant differences for other outcomes, or for hospital resource utilization ( Table 2) . Clopidogrel recipients experienced similar ICU and length of hospital stay compared with the control group.
Finally, an interesting observation in the present study was the lack of increased risk of postoperative bleeding and blood transfusions in patients receiving a combined therapy of clopidogrel and aspirin. Despite the fact that it has been postulated that there is a synergistic effect on platelet inhibition exerted by the combination of clopidogrel and aspirin, similar data have already been reported. 13,29,30, 32 Leong et al, in a prospective study of 919 isolated CABG patients, reported no differences in postoperative bleeding and blood transfusions between subjects taking clopidogrel and aspirin, and those taking clopidogrel alone. 13 And no differences were detected with regard to other outcomes and hospital resource utilization. 13 Gao et al also found no significant differences for surgical blood loss and transfusion volume in patients treated with clopidogrel plus aspirin compared to those taking clopidogrel alone. 32 
Study Limitations
The present study had several limitations, including all those inherent in any observational single-institution analysis. First, this was a retrospective observational investigation, and a selection bias may have been present, although we attempted to adjust for these differences by assessing the role of preoperative clopidogrel while stratifying on the propensity score. Second, the study was certainly limited in statistical terms with regard to the reduced number of observations. A type II error cannot be excluded in view of the number of patients in both groups, a difficulty shared with other studies analyzing the clopidogrel effect on postoperative bleeding and hemorrhagic complications. 6,8,12,32, 33 Additionally, the present study did not measure or control for the effect of postoperative transfusions on hospital outcome. We were unable to determine the real influence of transfusions on the risk of adverse postoperative outcomes. Although the impact of transfusions was not considered, previous studies have clearly shown their negative effects on patient recovery, increasing early and late morbidity and mortality. 17, 24 
Conclusions
Clopidogrel within 5 days of coronary surgery was an independent predictor for increased transfusion requirements, but not for other hemorrhagic complications such as re-exploration for bleeding or surgical blood loss. The combined preoperative therapy of clopidogrel and aspirin with respect to clopidogrel alone did not confer an additional risk for hemorrhagic complications or transfusion requirement.
